Archive

April 2025

Browsing

FPX Nickel Corp. (TSX-V: FPX) (OTCQB: FPOCF) (‘ FPX ‘ or the ‘ Company ‘) is pleased to announce the appointment of Dan Apai, P. Eng., as the Company’s Vice President, Projects effective May 1, 2025 . Mr. Apai succeeds Andrew Osterloh who will be departing his role as a Company employee on May 9, 2025 . Further, the Company is pleased to announce that Mr. Osterloh will be nominated for election as a Board member at the Company’s annual general meeting to be held on June 26, 2025 .

Martin Turenne , President and CEO of FPX stated, ‘On behalf of the Board of Directors, I would like to thank Andrew for his dedication and service to the Company. During Andrew’s tenure and under his leadership, the Company has significantly improved the development basis for the Baptiste Nickel Project, including progressing technical maturity in the areas of metallurgy, engineering, and execution planning. We are grateful for his efforts and wish him the very best going forward.’

Mr. Turenne continued, ‘I am delighted to welcome Dan to our senior management team. Dan has been a valuable contributor since he joined the Company in January 2023 as our Engineering Manager. Dan brings a wealth of knowledge from prior experience developing and commissioning multiple large-scale projects and his deep familiarity with Baptiste will ensure a smooth transition as we further advance the Project.’

‘We are very happy to welcome Andrew to the FPX Board,’ commented the Company’s Chairman, Peter Bradshaw . ‘Andrew has demonstrated exceptional leadership in progressing Baptiste through the development of the prefeasibility and refinery studies. His deep understanding of the Project and strategic insights will be a significant asset to our Board. We look forward to his contributions as a Board member to the Company’s continued success.’

Mr. Osterloh joined FPX in June 2021 , bringing with him extensive experience from project management roles at Fluor Canada and site operations positions at several notable mining projects, including Eskay Creek (that is now being redeveloped by Skeena Gold & Silver) and Huckleberry, operated by Imperial Metals, both located in British Columbia . Mr. Osterloh will be assuming the role of VP, Engineering & Construction at Skeena Gold & Silver, as the Company undertakes redevelopment of the Eskay Creek Project.

Mr. Apai, the Company’s Engineering Manager since January 2023 , has over twenty years’ mining industry experience in civil engineering and engineering management over a diverse range of projects. As Principal Civil Engineer for Fluor Canada, he led study and detailed engineering works for numerous large-scale mining projects for clients including Teck, Newmont, BHP, First Quantum, Glencore, Josemaria Resources, and Newcrest. Dan’s technical expertise includes site layout, earthworks, water management, linear facilities (i.e., roads, powerlines, pipelines), and water supply systems – all elements that strongly influence the capital intensity, permitability, and operability of mining projects. Mr. Apai is a Member of the Association of Professional Engineers of British Columbia and holds a Bachelor of Engineering from the University of Western Australia .

About the Baptiste Nickel Project

The Company’s Baptiste Nickel Project represents a large-scale greenfield discovery of nickel mineralization in the form of a sulphur-free, nickel-iron mineral called awaruite (Ni 3 Fe) hosted in an ultramafic/ophiolite complex. The absence of sulphur and our ability to connect to the BC Hydro grid means that Baptiste has the potential to be one of the lowest carbon-intensive nickel producers in the world and will produce a very high grade product that does not required any intermediate smelting or complex refining. The Baptiste mineral claims cover an area of 453 km 2 west of Middle River and north of Trembleur Lake, in central British Columbia . In addition to the Baptiste Deposit itself, awaruite mineralization has been confirmed through drilling at several target areas within the same claims package, most notably at the Van Target which is located 6 km to the north of the Baptiste Deposit. Since 2010, approximately US$55 million has been spent on the exploration and development of Baptiste.

FPX has conducted mineral exploration activities to date subject to the conditions of agreements with First Nations and keyoh holders.

About FPX Nickel Corp.

FPX Nickel Corp. is focused on the exploration and development of the Baptiste Nickel Project, located in central British Columbia , and other occurrences of the same unique style of naturally occurring nickel-iron alloy mineralization known as awaruite. For more information, please view the Company’s website at https://fpxnickel.com/ or contact Martin Turenne , President and CEO, at (604) 681-8600 or ceo@fpxnickel.com .

On behalf of FPX Nickel Corp.

‘Martin Turenne’
Martin Turenne , President, CEO and Director

Forward-Looking Statements

Certain of the statements made and information contained herein is considered ‘forward-looking information’ within the meaning of applicable Canadian securities laws. These statements address future events and conditions and so involve inherent risks and uncertainties, as disclosed in the Company’s periodic filings with Canadian securities regulators. Actual results could differ from those currently projected. The Company does not assume the obligation to update any forward-looking statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE FPX Nickel Corp.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2025/29/c3955.html

News Provided by Canada Newswire via QuoteMedia

This post appeared first on investingnews.com

Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol’ or the ‘Company’), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D., has been nominated to stand for election to the Company’s Board of Directors at its 2025 Annual General Meeting of shareholders to be held on May 28, 2025.

Dr. Garnett is a distinguished pharmaceutical industry executive with over 30 years’ experience, including two decades at Eli Lilly and Company, where he served as Chief Medical Officer from 2008 until his retirement in 2021. During his tenure at Eli Lilly, he led the successful development of therapeutics in women’s health, endocrinology, and neuroscience, resulting in multiple global commercial launches. Dr. Garnett has played a key role in the successful development of numerous drugs across both early- and late-stage clinical development. He has broad experience leading clinical development, portfolio management, medical affairs, regulatory strategy, and safety functional areas, and has a strategic understanding of the evolving metabolic therapy landscape.

‘We are pleased to nominate Dr. Garnett for election to our Board of Directors, as we mark a significant milestone with the recent initiation of patient enrollment in our pivotal Phase III MAVERIC trial,’ stated Guillermo Torre-Amione, M.D., Ph.D., Chair of Cardiol Therapeutics. ‘Dr. Garnett brings a wealth of industry experience and strategic vision, along with exceptional expertise in clinical development. His proven track record in guiding several drugs through regulatory approval and successful commercial launch will be instrumental in achieving our goal of making a meaningful difference for people living with underserved heart disease.’

Dr. Garnett currently serves as Chair of Ophirex and a Director of MapLight Therapeutics. In addition, he is a member of the Advisory Panel of Cambridge Innovation Capital and an equity partner at Recode Health Ventures LLC. Dr. Garnett holds a Bachelor of Medicine and Bachelor of Surgery (MBBS) from St. George’s, University of London. He is a Fellow of both the Faculty of Pharmaceutical Medicine (FFPM), and the Royal College of Obstetricians and Gynaecologists (FRCOG).

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration (‘US FDA’) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The ongoing ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward-looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx, and the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation of cannabidiol intended for use in heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian Securities Administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Supplement, the accompanying Base Prospectus and the documents incorporated by reference therein.

For further information, please contact:
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250087

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

NEWYou can now listen to Fox News articles!

It has been 100 days since the new U.S. administration took office amid a clear policy of ‘America First.’ 

But for American families like mine, families whose loved ones are still held hostage by Hamas for over 560 days, we should have already seen results from this policy. My son, Itay Chen, a dual U.S.-Israeli citizen, remains in captivity. So do four other Americans: Edan Alexander, Omer Neutra, Judy and Gadi Weinstein. Every day that passes without their return is another day of anguish, uncertainty, and pain.

As a father, I wake up every morning hoping this will be the day I get the call from the White House telling me my son is coming home. When President Donald Trump won the election, I felt a renewed sense of hope. I believed that his leadership, strength, and personal concern for American hostages would lead to real movement. And I deeply thank President Trump for demanding the release of all hostages even before his inauguration that led to the release of 33 hostages in Gaza, including two U.S. citizens. 

I believe he cares profoundly, but the truth is, the first 100 days of this administration have not delivered what the president himself demanded – releasing all of the U.S. hostages in Gaza and sending a clear message that holding U.S. hostages anywhere is a liability, not an asset. 

This is not a critique made in anger. It is a plea made in desperation. I understand that diplomacy is complex. I know that the negotiations around hostages—especially in a war zone and involving multiple international actors— require discretion, patience, and nuance. But I also know that time is not on our side. As the weeks pass, the fear grows that the window to bring our loved ones back is narrowing and they will disappear forever.

We have seen this administration act boldly in other arenas to implement the America First policy, particularly when it comes to economic policy. Tariffs and financial pressure have already been deployed as tools of American strength. 

Why not apply similar pressure now to release the U.S. hostages? Instead of the administration being proactive, U.S. families like mine, out of despair, are taking matters into our own hands. We’ve been lobbying Congress to impose direct financial sanctions against Hamas, pressuring banks and financial institutions to freeze assets and urging stricter enforcement of existing measures. Just this month, U.S. families filed a lawsuit against Bashar Masri, an American businessman charging that he provided assistance in constructing infrastructure that allowed Hamas militants to carry out their cross-border rampage, including killing 45 U.S. citizens. We’ve urged the Administration, the Department of Justice and the Treasury to expand these efforts. 

The administration can, and must, do more. Americans – children, fathers, sisters – are all still being held in underground tunnels by a terrorist organization, in conditions we can barely imagine. The previous administration told the American families the way to release our family members would be via Israel as a proxy. Though the plan did not work, the Biden administration kept doubling down on the same plan despite not getting the expected results. 

The Trump administration inherited this policy and should re-evaluate the game plan. President Trump is an extremely gifted negotiator. His team successfully released several U.S. citizens from war zones with direct negotiations. As such, why is President Trump not directly negotiating for the release of U.S. citizens in Gaza, but instead using third parties such as Qatar to negotiate for the release of U.S. citizens? In January, we saw what the president’s direct involvement can do to release hostages. The U.S. has a legal obligation to get its citizens out of harm’s way and if the proxy is not capable of releasing them, then the U.S. must find a different path to release its citizens.  

Trump administration officials have sent a clear message to the world that American lives are not bargaining chips. This administration has the opportunity to reinforce that principle—to lead with strength and show that ‘America First’ means never leaving Americans behind.

I will not lose hope. My faith in America’s power and promise is unbroken. But that hope needs to be matched with action. For Itay. For the other hostages. For the credibility – and the soul – of a nation that is seeking to reset the table with the world based on a true ‘America First’ policy. What a victory it would be if President Trump, in his upcoming visit to the Middle East, will bring on his plane back home the 5 U.S. hostages from Gaza.

This post appeared first on FOX NEWS

Rep. Marie Gluesenkamp Perez, D-Wash., described Rep. Nancy Pelosi, D-Calif., during her 2022 campaign as unrepresentative of American voters, but campaign finance reports revealed she collected at least $31,000 from the former House speaker and her political action committees during her three years in Congress. 

‘I want to make my position clear that I will not vote for Nancy Pelosi as Speaker of the House,’ Perez told The Columbian in 2022. ‘I look around, I look at my community, and I don’t see leadership in Congress looking like that.’

Despite the moderate Democrat rejecting Pelosi’s leadership on the campaign trail, campaign finance reports show that since she took office in 2022, Gluesenkamp Perez and her Super PAC, Marie Gluesenkamp Perez Campaign Defense Fund, have accepted at least $31,000 from Pelosi and her affiliated Super PACs, including PAC to the Future and Nancy Pelosi for Congress.

According to U.S. Census data, the $31,000 represents more than one third of the median household income for residents in Washington’s third congressional district, which includes Clark County and Vancouver, Washington, the district’s largest city.

‘We need more and more normal people to run for Congress. We need more people that work in the trades,’ Gluesenkamp Perez told Politico in 2023, as she described a Democratic Party out of touch with middle-class Americans. 

‘Just like her pal Nancy Pelosi, Marie Gluesenkamp Perez will say and do anything to get elected,’ Congressional Leadership Fund, the super PAC dedicated to maintaining the Republican majority in the U.S. House of Representatives, spokeswoman Torunn Sinclair, told Fox News Digital. 

‘That’s not a quality Washington State families want in their congresswoman.’

Gluesenkamp Perez was first elected to represent Washington in the U.S. House of Representatives in 2022 and won re-election in 2024, narrowly defeating her Republican challenger, Joe Kent, for the second time in two House cycles. 

The Washington congresswoman is considered one of the most vulnerable House Democrats in 2026, just as she was in 2024 after winning her 2022 race by less than two points. Republicans are likely to target her seat as an opportunity to widen their majority in the House. 

While Republicans slam Gluesenkamp Perez for flip-flopping on Pelosi, she is also facing the fury of her own party as hundreds of Democratic constituents protested at her town hall on Thursday. 

According to local reporting, including KGW News, protesters held up signs that read, ‘Shame on you,’ and chanted, ‘Vote her out,’ as Gluesenkamp Perez explained why she voted in support of the Safeguarding American Voter Eligibility (SAVE) Act. 

The SAVE Act, which passed in the House earlier this month, requires voters to obtain proof of citizenship in-person before they register for a federal election and will remove noncitizens from voter rolls. It has been widely rejected by Democrats since its conception, and 208 House Democrats voted against the bill. 

‘I do not support noncitizens voting in American elections – and that’s common sense to folks in Southwest Washington. Voting in our nation’s elections is a sacred right belonging only to American citizens, and my vote for the SAVE Act reflects that principle,’ Gluesenkamp Perez said after voting in support of the SAVE ACT, despite facing vocal opposition from constituents on Thursday for doing so. 

Gluesenkamp Perez also faced disapproval from Washington state Democrats for voting to censure Rep. Al Green, D-Texas, after he shouted and shook his cane during President Donald Trump’s joint address to Congress earlier this year.  

Gluesenkamp Perez’s campaign did not respond to Fox News Digital’s request for comment by deadline. 

This post appeared first on FOX NEWS

President Donald Trump’s second term has taken the world by storm in his first 100 days, leaving allies and adversaries scrambling to respond to new U.S. tariffs, stalled peace negotiations and hardball diplomacy from the White House.

On the campaign trail, he pledged to hit allies and foes alike with massive tariffs, end Russia’s war in Ukraine within 24-hours and threatened that ‘all hell’ would break out if all hostages were not freed from the clutches of Hamas in Gaza by the time he entered the Oval Office.

While Trump has been able to make good on some of his promises, other ambitions remain unmet. Here’s what Trump has accomplished and what challenges remain:

Where Russia’s war in Ukraine stands

Trump last week conceded that his pledge to end the three-year-old war in Ukraine within 24 hours of taking office was ‘figurative,’ acknowledging it was never a realistic goal. The conflict has claimed a reported 1 million casualties.

‘I said that as an exaggeration,’ he told reporters. 

While Trump has faced criticism over his ability to bring Russian President Vladimir Putin to the negotiating table, his team — led by Special Envoy Steve Witkoff and Secretary of State Antony Rubio — has made some headway, securing a 30-day ceasefire protecting Ukraine’s energy infrastructure.

But Putin has so far refused to enter any other brokered agreements, despite Kyiv’s willingness to play ball even after the historic Oval Office blow-up between Trump and Ukrainian President Volodymyr Zelenskyy in February.

Though Trump appeared to hold a grudge against Zelenskyy after Ukraine rejected a proposed mineral deal — even blaming him in part for Russia’s illegal invasion — relations between the two leaders appeared to improve over the weekend. Trump also set a new ultimatum for Putin, issuing a deadline to reach a ceasefire deal.

‘Two weeks or less,’ Trump told reporters Sunday, though he later added a bit more time would be acceptable. ‘We’ll see what happens over the next few days. We’ll probably learn a lot.’

Trump said he was ‘surprised and disappointed’ after Putin last week levied a barrage of missiles at Ukraine’s capital city of Kyiv in a strike that killed 12 civilians and injured nearly 100 more.

‘I want him to stop shooting, sit down and sign a deal,’ Trump said in reference to Putin. ‘We have the confines of a deal, I believe, and I want him to sign it and be done with it and just go back to life.’

Trump has not said how or whether he will hold Putin accountable if he doesn’t agree to a ceasefire and the White House has not responded to Fox News Digital’s repeated questions regarding the issue.

Gaza ceasefire

Before entering office, Trump repeatedly threatened Hamas that ‘all hell’ would break out if they didn’t return all hostages by the time he arrived at the White House. 

But the Palestinian terror group has ignored his threats and rejected Trump’s February proposal to turn the Gaza Strip into the ‘Riviera of the Middle East,’ saying it would adhere to a ceasefire agreement brokered between the terrorist organization and Israel, mediated by the U.S., Qatar and Egypt. 

Trump has not hit Hamas, nor have his negotiations to release hostages looked all that different from his predecessor’s.  

The first phase of what was intended to be a three-phase ceasefire saw the return of 33 hostages taken by Hamas, the majority of whom were abducted in the Oct. 7, 2023 attack on Israel, as well as the release of 1,800 Palestinian prisoners held by Jerusalem. 

But 59 hostages remain in Gaza, including American-Israeli Edan Alexander, and hopes of a second phase collapsed after negotiations stalled on terms surrounding future hostage releases, and in March Israel reignited military operations in the Gaza Strip.

A Qatari official on Sunday said the main hiccup in securing a ceasefire following the latest round of talks last week is that Israel has not presented a clear solution to end the war in exchange for hostage releases, Reuters reported. 

Trump on Friday said he pushed Israeli Prime Minister Netanyahu to reopen aid corridors into Gaza, which have been blocked since March 2, in order to allow food and medicine to reach Palestinians, though humanitarian corridors have not yet been opened. 

Iran nuclear agreement

Trump on Sunday said he believes a deal to end Iran’s nuclear program can be achieved ‘without having to start dropping bombs all over the place.’

Details on nuclear negotiations between the U.S. and Iran in Oman on Saturday, in which the third round of talks were held, remain nil, though Iranian Foreign Minister Abbas Araghchi reportedly told Iranian state media they were ‘very serious and work-focused.’ 

Araghchi described the hours-long talks as having finally ‘entered into deeper and more detailed discussions,’ though no specifics of the negotiations have been released. 

It remains unclear if the Trump administration is pursuing a halt to Tehran’s nuclear advancement or a complete disarmament arrangement, which would see the destruction of Iran’s centrifuge facilities and its stockpiles of near-weapons-grade enriched uranium. 

It also remains unclear how much time the president will allow for the negotiations to carry on. 

Relations with China deteriorate

Relations between the U.S. and China have hit a level of animosity not seen between the two superpowers since Washington normalized ties with the Chinese Communist Party (CCP) in the 1970s. 

The initial U.S.-China trade war started during Trump’s first term, in which he hit China with 25% tariffs on $50 billion in Chinese goods in April 2018.

Beijing responded by slapping reciprocal tariffs on $50 billion worth of U.S. goods, mostly targeting U.S. agricultural products worth some $16.5 billion — a trade war that saw the loss of a quarter of a million U.S. jobs by January 2021, according to the U.S.-China Business Council (USCBC).

From the campaign trail, Trump threatened to hit China with 60% tariffs — which he nearly did in early April when he announced an additional 34% tariff on top of the existing taxes already in place. 

But what had already sent geopolitical shockwaves and sparked near-immediate market concerns was further escalated just over a week later when Trump ratcheted up tariffs on Beijing to 145%. 

China has responded by hitting Washington with its own 125% reciprocal tariffs on U.S. imports and, according to a Bloomberg report on Monday, cargo supply shipments have already dropped by 60%.

Americans are expected to begin feeling the pains of the trade war come mid-May.

Trump said last week he had reached some 200 trade deals with countries affected by his sweeping tariffs — measures that hit nearly every U.S. trading partner, including longtime allies. He paused the tariffs for 90 days earlier this month following intense backlash.

The status of trading relations with U.S. partners remains unclear, along with whether the administration will implement the blanket tariffs on those nations come July.

The 25% tariffs on steel, aluminum and imported vehicles remain in effect.

The White House did not directly respond to Fox News Digital’s questions regarding next steps Trump will takes when it comes to handling thus far unresolved conflict in Ukraine and the Gaza Strip.

A White House spokesman instead said, ‘President Trump inherited widespread foreign conflicts and a weak standing on the world stage from Joe Biden. Now, America is strong again, hostages are free from Gaza, Marc Fogel and Ksenia Karelina are home, hundreds of Houthi and other terrorists have been eliminated, and we are closer to peace than ever before. 

‘This President will never get the credit he deserves for his vast foreign policy accomplishments, but Americans know they are freer and safer under his leadership,’ the spokesman added.

This post appeared first on FOX NEWS

President Donald Trump has spent the first 100 days of his second White House term signing a flurry of executive orders aimed at delivering on his policy priorities: slashing government spending, cracking down on illegal immigration and eliminating many diversity and equity initiatives enacted under the Biden administration.

The more than 150 executive orders Trump has signed far outpace those of his predecessors. But they have also triggered a torrent of lawsuits seeking to block or pause his actions, teeing up a high-stakes showdown over how far Trump can push his Article II powers before the courts can or should intervene. 

It’s a looming constitutional clash spinning like a top through the federal courts; a blink-and-you’ll-miss-it set of hearings and appeals and emergency orders that deal with weighty issues of due process and First Amendment protections guaranteed by the Constitution. 

Trump’s critics argue the fast-paced strategy is meant to confuse and overwhelm his opponents. His supporters counter that it allows him to strike with maximum precision and sidestep a clunky, slow-moving Congress as the president pursues his top priorities.

In his first 100 days, administration lawyers have gone to bat in courtrooms across the country to defend Trump’s early executive orders and halt a wave of lawsuits and emergency restraining orders aimed at blocking them. 

Trump, meanwhile, has steadfastly maintained that he would ‘never defy’ the Supreme Court as recently as in an interview last week. 

‘I’m a big believer in the Supreme Court and have a lot of respect for the justices,’ Trump told Time Magazine.  

Critics say he already has.

‘The second Trump administration has taken the guardrails off of the norms that historically governed the rule of law and is undertaking steps to enhance the perceived power of the executive branch to the detriment of the two other co-equal branches,’ Mark Zaid, an attorney who has gone toe-to-toe with the Trump administration in several court cases this year, told Fox News Digitial.

‘These actions threaten the fundamental notion of our democracy, particularly as the Administration seeks to eliminate due process protections in a quest for power.’

The biggest fights so far have centered around the Trump administration’s use of the Alien Enemies Act, a 1798 wartime law, to deport certain migrants to El Salvador. Another major case to watch will be challenges to Trump’s executive order ending birthright citizenship. 

Two separate federal judges, in D.C. and Maryland, have suggested they could move to begin possible contempt proceedings against some Trump officials for refusing to comply with their orders.

In one case, a judge issued a scathing rebuke against Trump officials for failing to return a Maryland resident and alleged gang member who was wrongfully deported to El Salvador this year. Separately, U.S. District Judge James Boasberg said there was probable cause to find Trump administration officials in criminal contempt for defying his order to return deportation flights to El Salvador on March 15.

The Trump administration has fought back, questioning the authority of lower courts to stop his agenda. The Supreme Court agreed to hear oral arguments on a challenge to some of the nationwide injunctions, beginning with a birthright citizenship case in early May.

Meanwhile, White House officials have railed against the ‘activist’ judges who they say have overstepped and are acting with a political agenda to block Trump’s policies. They’ve blasted judges for pausing Trump’s transgender military ban, reinstating USAID programs and blocking Elon Musk’s Department of Government Efficiency (DOGE) from accessing federal offices.

Some congressional allies have threatened impeachment against judges who defy Trump, but so far Congress has not advanced any impeachment articles.

White House press secretary Karoline Leavitt declined this week to rule out the arrest of federal judges, including Supreme Court justices.

Asked at a press briefing about the hypothetical on Monday, Leavitt referred the matter to the Justice Department but said a judge in New Mexico was arrested in ‘a clear-cut case of obstruction.’

‘And so anyone who is breaking the law or obstructing federal law enforcement officials from doing their jobs is putting themselves at risk of being prosecuted, absolutely,’ she said.

Jonathan Turley, a law professor and Fox News contributor, told Fox News Digital that he sees Trump’s early actions as getting ahead of the 2026 primaries and moving with maximum force to implement his agenda.

Trump ‘knows that he has no alternative but to push ahead on all fronts if he is going to make meaningful progress on his promised reforms,’ Turley told Fox News. 

‘The midterm elections are looming in 2026. If the Democrats retake the House, he knows that he can expect investigations, impeachments and obstruction. That means that he has to expedite these cases and establish his lines of authority in areas ranging from migration to the markets.’

This post appeared first on FOX NEWS

The House on Monday overwhelmingly passed a bill backed by first lady Melania Trump that cracks down on the posting of explicit images, including ‘deep fake’ nudes generated of people by artificial intelligence, without consent. 

The Tools to Address Known Exploitation by Immobilizing Technological Deepfakes on Websites and Networks – known as the TAKE IT DOWN Act – was approved by a 409-2 vote and now heads to President Donald Trump’s desk. 

The measure ‘generally prohibits the nonconsensual online publication of intimate visual depictions of individuals, both authentic and computer-generated, and requires certain online platforms to promptly remove such depictions upon receiving notice of their existence,’ according to the bill summary. 

It specifically prohibits online publication of ‘intimate visual depictions’ of an adult subject ‘where publication is intended to cause or does cause harm to the subject, and where the depiction was published without the subject’s consent or, in the case of an authentic depiction, was created or obtained under circumstances where the adult had a reasonable expectation of privacy,’ as well as ‘a minor subject where publication is intended to abuse or harass the minor or to arouse or gratify the sexual desire of any person.’ 

‘Violators are subject to mandatory restitution and criminal penalties, including prison, a fine, or both,’ according to the bill summary. ‘Threats to publish intimate visual depictions of a subject are similarly prohibited under the bill and subject to criminal penalties.’ 

The legislation also requires platforms to establish a process where victims of revenge porn can notify them of the existence of images and request removal. The bill says platforms then have 48 hours to remove those images.

Sen. Ted Cruz, R-Texas, introduced the TAKE IT DOWN Act in January, and it was approved by the upper chamber in February. It was brought to the House by Rep. Maria Salazar, R-Fla.

Two Republicans – Reps. Thomas Massie of Kentucky and Eric Burlison of Missouri – were the only House members to vote against the legislation on Monday.  

Massie acknowledged that the TAKE IT DOWN Act ‘would impose federal criminal and civil penalties for publishing unauthorized intimate pictures generated with AI.’

‘I’m voting NO because I feel this is a slippery slope, ripe for abuse, with unintended consequences,’ Massie wrote on X. 

House Republicans on Monday praised the first lady, Cruz and Salazar for leading the ‘crucial legislation’ to ‘create a safer digital future and protect our kids from deepfake exploitation.’ 

‘The passage of the TAKE IT DOWN Act is a historic win in the fight to protect victims of revenge porn and deepfake abuse,’ Cruz wrote on X. ‘This victory belongs first and foremost to the heroic survivors who shared their stories and the advocates who never gave up. By requiring social media companies to take down this abusive content quickly, we are sparing victims from repeated trauma and holding predators accountable.’

‘This day would not have been possible without the courage and perseverance of Elliston Berry, Francesca Mani, Breeze Liu, and Brandon Guffey, whose powerful voices drove this legislation forward,’ the senator wrote, adding that he was especially grateful to colleagues, including Melania Trump and Salazar, as well as Democrats Sen. Amy Klobuchar of Minnesota, and Rep. Madeleine Dean of Pennsylvania, ‘for locking arms in this critical mission to protect Americans from online exploitation.’

‘Advancing this legislation has been a key focus since I returned to my role as First Lady this past January,’ Melania Trump wrote on X. ‘I am honored to have contributed to guiding it through Congress. By safeguarding children from hurtful online behavior today, we take a vital step in nurturing our leaders of tomorrow. #BeBest’ 

During President Trump’s first term, the first lady established the BE BEST awareness campaign, which ‘focused on the well-being of children and highlighted the people and programs dedicated to ensuring a better future for the next generation,’ according to the White House. Melania Trump also established Fostering the Future, a BE BEST initiative, ‘which provides college-level scholarships to those aging out of the foster care system.’

This post appeared first on FOX NEWS

“60 Minutes” correspondent Scott Pelley paid tribute Sunday to Bill Owens, the show’s executive producer who resigned last week, saying on the air that “none of us is happy” about the extra supervision that corporate leaders are imposing.

Pelley made his comments at the end of the evening’s CBS News telecast, saying that in quitting, Owens proved he was the right person for the job.

“It was hard on him and it was hard on us,” Pelley said. “But he did it for us — and you.”

His on-air statement was an unusual peek behind the scenes at the sort of inner turmoil that viewers seldom get the opportunity to see.

Owens, only the third top executive in the 57-year history of television’s most influential newscast, resigned last week, saying he no longer felt he had the independence to run the program as he had in the past, and felt necessary.

CBS News’ parent company, Paramount Global, is in the midst of a merger with Skydance Media that needs the approval of the Trump administration. Trump has sued “60 Minutes” for $20 billion, saying it unfairly edited a Kamala Harris interview last fall to her advantage. Owens and others at “60 Minutes” believe they did nothing wrong and have opposed a settlement.

As a result, Pelley explained to viewers on Sunday, Paramount has begun to supervise “60 Minutes” stories in new ways. Former CBS News President Susan Zirinsky, a longtime news producer, has reportedly been asked to look at the show’s stories before they air.

“None of our stories has been blocked,” Pelley said. “But Bill felt he lost the independence that honest journalism requires. No one here is happy about it. But in resigning, Bill proved he was the right person to lead ‘60 Minutes’ all along.”

Despite this, “60 Minutes” has done tough stories about the Trump administration almost every week since the inauguration in January, many of them reported by Pelley. On Sunday, “60 Minutes” correspondent Sharyn Alfonsi had the latest, interviewing scientists about cutbacks at the National Institutes for Health.

Trump was particularly angered by the show’s telecast two weeks ago, saying on social media that CBS News should “pay a big price” for going after him.

This post appeared first on NBC NEWS

International Business Machines Corporation on Monday announced it will invest $150 billion in the U.S. over the next five years, including more than $30 billion to advance American manufacturing of its mainframe and quantum computers.

“We have been focused on American jobs and manufacturing since our founding 114 years ago, and with this investment and manufacturing commitment we are ensuring that IBM remains the epicenter of the world’s most advanced computing and AI capabilities,” IBM CEO Arvind Krishna said in a release.   

The company’s announcement comes weeks after President Donald Trump unveiled a far-reaching and aggressive “reciprocal” tariff policy to boost manufacturing in the U.S. As of late April, Trump has exempted chips, as well as smartphones, computers, and other tech devices and components, from the tariffs.

IBM said its investment will help accelerate America’s role as a global leader in computing and fuel the economy. The company said it operates the “world’s largest fleet of quantum computer systems,” and will continue to build and assemble them in the U.S., according to the release.

IBM competitor Nvidia, the chipmaker that has been the primary benefactor of the artificial intelligence boom, announced a similar push earlier this month to produce its NVIDIA AI supercomputers entirely in the U.S. 

Nvidia plans to produce up to $500 billion of AI infrastructure in the U.S. via its manufacturing partnerships over the next four years.

Last week, IBM reported better-than-expected first-quarter results. The company said it generated $14.54 billion in revenue for the period, above the $14.4 billion expected by analysts. IBM’s net income narrowed to $1.06 billion, or $1.12 per share, from $1.61 billion, or $1.72 per share, in the same quarter a year ago.

IBM’s infrastructure division, which includes mainframe computers, posted $2.89 billion in revenue for the quarter, beating expectations of $2.76 billion.

The company announced a new z17 AI mainframe earlier this month.

CNBC’s Jordan Novet contributed to this report.

This post appeared first on NBC NEWS